Effects of TM02® Supplementation on Immune Function in Children

This randomized, double-blind, placebo-controlled clinical study evaluated the effects of 12 weeks of TM02® supplementation on immune-related outcomes in generally healthy children aged 2 to 12 years. Participants were randomized to receive either TM02® or a matching placebo for 12 weeks. Immune-related assessments were performed at baseline and at Weeks 4, 8, and 12. Outcomes included salivary immunoglobulin A (IgA), interleukin-2 (IL-2), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), the Immune Status Questionnaire (ISQ), and Visual Analogue Scale (VAS) for immunity status, when participants experienced illness. Safety and tolerability were monitored throughout the study.